Login / Signup

Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer.

Yoon-Koo KangYung-Jue BangShunsuke KondoHyun Cheol ChungKei MuroIsabelle DussaultChristoph HelwigMotonobu OsadaToshihiko Doi
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
In this first evaluation in Asian patients with heavily pretreated advanced GC/GEJC, bintrafusp alfa demonstrated a manageable safety profile and clinical activity.
Keyphrases
  • replacement therapy
  • transforming growth factor
  • cancer therapy
  • clinical trial
  • drug delivery
  • placebo controlled